MedPageToday
MedPage Today) — Zenocutuzumab (Bizengri), a bispecific antibody against HER2 and HER3, showed efficacy in patients with advanced NRG1 fusion-positive cancers, particularly non-small cell lung cancer (NSCLC) and pancreatic cancer, according to…
Read More
New Bispecific Shrinks NRG1 Fusion-Positive Lung, Pancreatic Tumors
MedPage Today) — Zenocutuzumab (Bizengri), a bispecific antibody against HER2 and HER3, showed efficacy in patients with advanced NRG1 fusion-positive cancers, particularly non-small cell lung cancer (NSCLC) and pancreatic cancer, according to…